- $14.53m
- $16.61m
- $2.29m
Brief: Pharmacyte Biotech Acquires $5 Million Stake In Emerging Women’S Health Innovator Femasys
Brief: Femasys Inc. Secures Additional Financing With Strategic Investment From Investors Led By Pharmacyte Biotech
Brief: Femasys Received Notice From Nasdaq Informing Co It Has Regained Compliance With Nasdaq’S Listing Rule
Brief: Femasys Inc. Regains Compliance With Nasdaq Listing Requirements
U.S. RESEARCH ROUNDUP-Apollo Global Management, Draftkings, TFI International
Femasys gains on FDA clearance to market its infertility treatment
Brief: Femasys Inc. Receives U.S. FDA Clearance To Market Femaseed, An Innovative Infertility Treatment Solution
Brief: Femasys Inc. Q2 EPS USD -0.22
Brief: Femasys Initiates Enrollment In Pivotal Trial Of Its Permanent Birth Control Candidate Fembloc
Brief: Femasys Announces Notice Of Allowance For New U.S. Patent Application Covering Use Of FemBloc For Female Permanent Birth Control
Brief: Femasys Announces FDA Approval Of Its Ide For The Pivotal Clinical Trial Of FemBloc Permanent Birth Control, A Non-Surgical Alternative For Women
Brief: Femasys Files For Offer And Resale Of Up To 3.4 Mln Common Stock
Brief: Femasys' Ultrasound-Based Diagnostic Test Receives Product Approval In Canada
Brief: Femasys Inc Receives Notice Of Delisting Or Failure To Satisfy A Continued Listing Rule Or Standard From Nasdaq
Brief: Femasys Inc. Announces Financial Results For The First Quarter Ended March 31, 2023
Brief: Femasys’Femcerv Endocervical Tissue Sampler For Cervical Cancer Diagnosis Receives Product Approval In Canada
Brief: Femasys Announces $3.9 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
Brief: Femasys Inc Femaseed Localized Directional Insemination For Infertility Receives Product Approval In Canada
Brief: Femasys Reports 2022 Loss Per Share Of $0.96